# CD83 Receptor Unveiled as a Therapeutic Target in Metastatic Breast Cancer through Single-Cell RNA-Seq

Saed Sayad, MD, PhD	Mark Hiatt, MD, MBA, MS	Hazem Mustafa, DDS, MSc
Bioada Lab	Bioada Lab	Bioada Lab
saed@bioada.com	mark@bioada.com	hazem@bioada.com

## Abstract

**Background.** Metastatic breast cancer is an advanced stage of the disease in which cancer cells have spread to organs beyond the breast, posing a significant clinical challenge, necessitating the development of novel therapeutic approaches. Gaining a profound understanding of the intricacies of metastasis is essential for developing effective interventions. In this study, we investigated the CD83 gene and its receptor as a promising therapeutic target in metastatic breast cancer.

*Method.* We obtained single-cell transcriptomes (*GSE75688*) from the NIH portal website. These transcriptomes encompassed samples from eleven patients (BC01-BC11), which included two lymph node metastases (BC03LN, BC07LN). Our analysis focused on identifying genes with distinct expression patterns between metastatic and primary single cells.

**Results.** In the array of 22 tables (comprising two metastatic and eleven primary tables) featuring the top 800 differentially expressed genes in each, CD83 stood out as the sole significantly upregulated gene consistently shared across all eleven patients at the intersection. CD83 is a protein that plays a crucial role in the immune system, particularly in the context of antigen presentation, immune regulation and immune checkpoint, suggesting its potential involvement in breast cancer progression and metastasis. Based on these findings, we hypothesized that blocking the CD83 receptor on the cell membrane using an antibody could effectively inhibit cell growth in metastatic breast cancer.


**Conclusion**. We propose a novel therapeutic approach by targeting the CD83 receptor on the cell membrane to inhibit cell growth and metastasis in breast cancer. While these findings are promising, further research is needed to validate the efficacy and safety of CD83-targeted therapies. If successful, such treatments could offer improved options for patients with metastatic breast cancer, addressing a critical need for more effective interventions in advanced stages of the disease.


## Introduction

Metastatic breast cancer represents the advanced stage of this daunting disease, marking a critical juncture in its progression. At this stage, cancer cells have spread beyond the breast and nearby lymph nodes to other organs, such as the lungs, liver, bones, and brain, posing significant challenges to effective treatment. Unlike localized breast cancer, metastatic breast cancer requires a comprehensive and nuanced approach due to its systemic nature. Understanding the intricacies of metastasis is pivotal in developing targeted therapies and interventions that can make a meaningful impact in the battle against this formidable adversary. The survival rates for metastatic breast cancer vary based on several factors. In the United States, the 5-year relative survival rate for women with metastatic breast cancer is 30% [1]. Cluster of Differentiation (CD) proteins emerge as key players influencing tumor development, metastasis, and therapeutic responses. CD proteins in breast cancer signify their multifaceted roles in diagnosis [2], prognosis [3], immune modulation [4], targeted therapy [5], metastasis [6], and treatment resistance [7]. Importantly, while some CD proteins may promote metastasis, others may act as tumor suppressors, inhibiting the spread of cancer cells. In this study, we focused on CD83, a cell surface receptor found to be upregulated in single cells extracted from breast cancer patients.

## Data

We downloaded single-cell transcriptomes (*GSE75688*) from the NIH portal website. All single-cell mRNA expression profiles (**Figure 1**) were acquired from eleven patients (BC01-BC11), including two lymph node metastases (BC03LN, BC07LN). We applied a log2 transformation to the dataset prior to analysis.





## **Data Analysis**

In this study, we performed a comprehensive comparative analysis focusing on the single-cell transcriptomes of both primary and metastatic breast cancer. This investigation aimed to unravel the detailed patterns of gene-expression patterns underlying the progression of the disease. With single-cell transcriptomes allowing us to examine individual cells, we could discern subtle variations in gene-expression profiles, gaining insights into the diverse cell populations that contribute to the dynamic nature of breast-cancer progression. The primary tumor serves as the origin point of malignancy, and understanding the transcriptomic alterations occurring at this site is crucial for deciphering the initial stages of cancer development. We went further in our study, looking at metastatic lesions. This gave us a special view of how cancer cells change at the molecular level to spread and grow in other parts of the body.

## Differential Gene Expression – Primary Cells against Metastatic Cells

Using the t-test, we compared the primary breast cancer cells (422 cells from eleven patients) with the metastatic cells from two patients (110 cells) to find differentially expressed genes (**Figure 2**). This statistical comparison provides insight into molecular distinctions between primary and metastatic cancer cell populations, contributing valuable information to our understanding of breast-cancer dynamics.




Figure 2: Breast cancer primary single cells from eleven patients and metastatic cells from two patients.


Out of many differentially expressed genes, we selected top ten upregulated and downregulated genes (**Table 1**) that represent a diverse range of biological pathways and functions, but are especially connected to the immune system.


Top 10 Differentially Expressed Genes – Primary Cancer Cells against Metastatic Cancer Cells			
Upregulated		Downregulated	
Gene Symbol	Gene Name	Gene Symbol	Gene Name
MS4A1	Membrane Spanning 4-Domains A1	S100A6	S100 Calcium Binding Protein A6
CD79B	CD79b Molecule	S100A16	S100 Calcium Binding Protein A16
LRMP	Inositol 1,4,5-Triphosphate Receptor Associated 2	MT-ND3	Mitochondrially Encoded NADH
CD83	CD83 Molecule	MGP	Matrix Gla Protein
FCRLA	Fc Receptor Like A	TCF7L2	Transcription Factor 7 Like 2
PAX5	Paired Box 5	CD63	CD63 Molecule
LY9	Lymphocyte Antigen 9	IFI6	Interferon Alpha Inducible Protein 6
CD69	CD69 Molecule	PFN2	Profilin 2
SNX29P2	Sorting Nexin 29 Pseudogene 2	MT-ND1	Mitochondrially Encoded NADH
POU2AF1	POU Class 2 Homeobox Associating Factor 1	НК2	Hexokinase 2

**Table 1**: Top ten upregulated and downregulated genes through primary and metastatic gene-expression analysis.

#### Differential Gene Expression – Primary Cancer Cells against Primary Cancer Cells

We identified numerous differentially expressed genes upon comparing primary cancer cells with metastatic cancer cells, assuming homogeneity within the primary cancer-cell population. To scrutinize this assumption, we systematically compared primary cancer cells from one patient against those from other patients in eleven separate analyses. Across all paired comparisons, we consistently observed significant upregulation and downregulation of genes. This finding implies that the assumption of all primary cancer cells belonging to a single population is untenable. The differential gene-expression patterns observed in our analyses underscore the importance of considering inter-patient variability in future studies, as it contributes crucial insights into the complexities of cancer biology. The specific case of BC01 against BC02 serves as a representative example (**Figure 3**). We chose the top ten upregulated and downregulated genes (**Table 2**) from a pool of differentially expressed genes, highlighting their significance in diverse biological pathways.





Top 10 Differentially Expressed Genes – Primary Cancer Cells against Primary Cancer Cells			
Upregulated		Downregulated	
Gene Symbol	Gene Name	Gene Symbol	Gene Name
MGP	Matrix Gla Protein	RP4-765C7.2	Pseudogene
ADIRF	Adipogenesis Regulatory Factor	PRKACB Protein Kinase CAMP	
IFITM1	Interferon Induced Trans. Protein 1	LINC00578	Long Intergenic Non-Protein Coding
C4A	Complement C4A	MGLL	Monoglyceride Lipase
ANKRD30A	Ankyrin Repeat Domain 30A	NFIB	Nuclear Factor I B
C4B	Complement C4B	CNKSR3	CNKSR Family Member 3
SERPINA3	Serpin Family A Member 3	FAM198B	Golgi Associated Kinase 1B
TIMP1	TIMP Metallopeptidase Inhibitor 1	EHF	ETS Homologous Factor
IFITM2	Interferon Induced Trans. Protein 2	ANKRD30B	Ankyrin Repeat Domain 30B
AGR3	Anterior Gradient 3	СКВ	Creatine Kinase B

 Table 2: Top ten upregulated and downregulated differentially expressed genes for two patients (BC01 & BC02).

#### Differential Gene Expression - Comparing Primary Cancer Cells within a Single Patient

We demonstrated that assuming the primary cancer cells from eleven patients originate from a single population is not valid. In our investigation of cancer-cell heterogeneity in a single patient (BCO1), we randomly divided the cells into two subsets (**Figure 4**) and employed a t-test to identify differentially expressed genes. However, no significant upregulated or downregulated genes were observed for BCO1 or the other ten patients.




Figure 4: Breast cancer primary single cells from one patient (BC01) divided to two subsets randomly.

#### Differential Gene Expression – Metastatic Cancer Cells against Metastatic Cancer Cells

Through a comparison between primary cancer cells and metastatic cancer cells we showed that there are many differentially expressed genes, initially assuming homogeneity within the metastatic cancer cell population. In order to assess this assumption, we systematically compared metastatic cancer cells from one patient with those from another (**Figure 5**). Our findings revealed that the assumption of a unified population among all metastatic cancer cells is untenable. The distinctive patterns of gene expression observed in our analyses underscore the necessity of acknowledging inter-patient variability in future studies, as it provides essential insights into the intricacies of cancer biology. To further elucidate the significance of these findings, we selectively identified the top ten upregulated and downregulated genes (**Table 3**) from a pool of differentially expressed genes, highlighting their significance in diverse biological pathways.




Figure 5: Breast cancer metastatic single cells from two patients (BC03LN and BC07LN).

Top 10 Differentially Expressed Genes – Metastatic Cancer Cells against Metastatic Cancer Cells			
Upregulated		Downregulated	
Gene Symbol	Gene Name	Gene Symbol	Gene Name
RPL9P8	Ribosomal Protein L9 Pseudogene 8	RP11-490G8.1	Pseudogene
RPL9P9	Ribosomal Protein L9 Pseudogene 8	RPL29P11	Ribosomal Protein L29 Pseudogene 11
MUCL1	Mucin Like 1	CCDC144B	Coiled-Coil Domain Containing 144B
CXADR	CXADR Ig-Like Cell Adhesion Molecule	KIF23	Kinesin Family Member 23
MGST1	Microsomal Glutathione S-Transferase	MELK	Maternal Embryonic Leucine Zipper Kinase
FABP7	Fatty Acid Binding Protein 7	CDK1	Cyclin Dependent Kinase 1
CD44	CD44 Molecule	RPSAP15	Ribosomal Protein SA Pseudogene 15
MARCKS	Myristoylated Alanine Rich Protein Kinase C Substrate	PRPSAP2	Phosphoribosyl Pyrophosphate Synthetase Associated Protein 2

TSPAN8	Tetraspanin 8	MZB1	Marginal Zone B And B1 Cell
YBX3	Y-Box Binding Protein 3	USP32P2	Ubiquitin Specific Peptidase 32 Pseudogene 2

Table 3: Top ten upregulated and downregulated differentially expressed genes for BC03LN against BC07LN.

#### Differential Gene Expression – Comparing Metastatic Cancer Cells Within a Single Patient

We demonstrated that assuming the metastatic cancer cells from two patients originate from a single population is not valid. In our investigation of cancer cell heterogeneity in a single patient (BC03LN), we randomly divided the cells into two subsets (**Figure 6**) and employed a t-test to identify differentially expressed genes, but no significant upregulated or downregulated genes were observed. We repeated the same analysis for the second sample (BC07LN) and did not observe any significant upregulated or downregulated genes.




Figure 6: Breast cancer metastatic single cells from one patient (BC03LN) divided to two subsets randomly.

#### Differential Gene Expression – Metastatic Cells against Primary Cells – Patient by Patient

Our findings revealed that the assumption of a unified population among all primary or metastatic cancer cells is untenable. We approached the analysis of each patient's cancer cells by treating them as independent samples. Utilizing a statistical analysis, we systematically compared metastatic cancer cells from each patient against all primary cancer cells (patient by patient). Subsequently, we identified and retained the top 800 upregulated and downregulated genes for each test. In **Table 4**, we presented the

top three upregulated and downregulated genes. Notably, the RP4-765C7.2 gene appeared in twelve out of the 22 top-three upregulated genes, while the IFI6 gene was featured in five out of 22 top-three downregulated genes. RP4-765C7.2 is a pseudogene with unknown functionality and IFI6 is one of the many genes induced by interferon [8]. We attempted to identify common genes among 22 tests from the initially saved set of 800 genes for each test. To our surprise, we discovered only one gene that was consistently present across all tests: *CD83*.

Metastatic	Primary	Upregulated Genes in Metastatic Cancer Cells	Downregulated Genes in Metastatic Cancer Cells
	BC01	CD74, HLA-DRA, HLA-DQB1	MGST1, FAM198B, LINC00578
	BC02	<b>RP4-765C7.2</b> , BIRC3, PTPRC	IFI6, ANKRD30A, MGST1
	BC03	PLEK, PSMB9, HLA-DQB1	SPANXB1, FAM174A, SPANXD
	BC04	MS4A1, RP11-490G8.1, LRMP	PPP1R1B, MTND2P28, S100A6
	BC05	BIRC3, CD74, HLA-DQB1	MGST1, ANKRD30A, LIMCH1
BC03LN	BC06	<b>RP4-765C7.2</b> , RP11-343H5.4, BTG1	MTND2P28, SLPI, WFDC2
	BC07	RP11-490G8.1, RPL29P11, CD79B	RPL9P9, RPL9P8, YBX3
	BC08	CD74, BIRC3, <b>RP4-765C7.2</b>	MGST1, YBX3, CALD1
	BC09	<b>RP4-765C7.2</b> , RP11-343H5.4, MS4A1	<b>IFI6</b> , IFI44, IFIT1
	BC10	<b>RP4-765C7.2</b> , BIRC3, CD74	CALD1, MIA, GABRP
	BC011	RP11-343H5.4, <b>RP4-765C7.2</b> , ELF1	MIA, MMP7, A2M
	BC01	GSTP1, RASGEF1B, RGS2	ANKRD30B, LINC00578, C19orf33
	BC02	<b>RP4-765C7.2</b> , GSTP1, RGS2	MGP, CA12, <b>IFI6</b>
	BC03	RPL9P8, RPL9P9, GSTP1	RP11-490G8.1, SPANXD, GSTM3
	BC04	MS4A1, ARHGDIB, UCP2	MTND2P28, H19, MSL1
	BC05	RGS2, HLA-B, CD74	ANKRD30A, PPP1R14C, RPL23
BC07LN	BC06	<b>RP4-765C7.2</b> , RPL9P8, RPL9P9	MTND2P28, AARD, LY6K
	BC07	MS4A1, LY9, CD79B	IFI27, ANXA1, <b>IFI6</b>
	BC08	BTG1, <b>RP4-765C7.2</b> , RPL9P8	MGP, GABRP, PAM
	BC09	<b>RP4-765C7.2</b> , RP11-343H5.4, NPIPB3	IFI6, GBP1, GBP5
	BC10	<b>RP4-765C7.2</b> , CDV3, RP11-742N3.1	MIA, GABRP, DSG3
	BC011	<b>RP4-765C7.2</b> , DUSP10, RP11-343H5.4	MIA, MMP7, PAM

Table 4: Top three upregulated and downregulated genes by comparing metastatic cells against primary cells.

The CD83 gene is located on human chromosome 6p23. In humans, a promoter 261 bp upstream consists of five NF- $\kappa$ B and three interferon regulatory factor binding sites, reflecting the involvement of CD83 in inflammation [9]. The CD83 protein is a transmembrane glycoprotein that plays pivotal roles in the immune system, particularly in the regulation of T-cell function and antigen presentation. Primarily expressed on the surface of mature dendritic cells (DCs), CD83 serves as a maturation marker, indicating the readiness of DCs to initiate immune responses. Significantly, the CD83 protein emerges as a potential Immune checkpoint [10]. Immune checkpoints are molecules or receptors that play a pivotal role in modulating the immune response, ensuring a delicate balance between activation and inhibition to prevent excessive immune reactions or autoimmunity.

## Discussion

We investigated the complex landscape of metastatic breast cancer, with a particular focus on understanding the significance of the CD83 gene. We conducted a thorough comparative analysis of single-cell transcriptomes derived from both primary and metastatic breast cancer cells. Contrary to the assumption of uniformity within these cell populations, this study revealed substantial variability among patients, challenging the notion of homogeneity. The molecular differences identified between primary and metastatic breast cancer cells provide a deeper understanding of the disease dynamics. The recognition of this heterogeneity emphasizes the necessity for a nuanced comprehension of cancer biology, considering the diverse gene-expression patterns that contribute to the intricacies of the illness. The findings not only underscore the importance of acknowledging heterogeneity, but also pinpoint specific genes, including RP4-765C7.2, IFI6, and CD83, which are shared across diverse patient samples. However, CD83 stood out as the sole significantly upregulated gene consistently shared across all eleven patients at the intersection.

The multifaceted functions of CD83 contribute to the orchestration of immune responses, making this gene a key player in maintaining immune homeostasis and regulating adaptive immune reactions. The role of CD83 in inflammation and its expression on various immune cells position it as a potential target for further exploration in developing targeted therapies. Moreover, recognizing CD83 as an immunity checkpoint adds a layer of complexity and hope to its significance in breast cancer, emphasizing its potential as a key factor in immune modulation and promising avenue for therapeutic interventions. Our study contributes valuable insights that could inform the development of targeted therapies and interventions, offering new approaches in the battle against metastatic breast cancer.

## Summary

This study focused on metastatic breast cancer, an advanced stage in which cancer cells have spread beyond the breast, posing significant treatment challenges. We analyzed single-cell transcriptomes (primary and metastatic) from eleven patients, identifying CD83 as consistently upregulated in metastatic cells. We thus propose blocking the CD83 receptor with an antibody as a novel means to inhibit metastatic breast cancer growth, and emphasize the need for further research to validate the efficacy and safety of this approach to improved treatment.

# References

- 1. American Cancer Society. Survival Rates for Breast Cancer. 2021.
- 2. Al-Othman N, Alhendi A, Ihbaisha M, Barahmeh M, Alqaraleh M, Al-Momany BZ. Role of CD44 in breast cancer. Breast Dis. 2020;39(1):1-13. doi: 10.3233/BD-190409.
- López C, Bosch R, Korzynska A, García-Rojo M, Bueno G, García-Fontgivell JF, Martínez González S, Gras Navarro A, Sauras Colón E, Casanova Ribes J, Roszkowiak L, Mata D, Arenas M, Gómez J, Roso A, Berenguer M, Reverté-Villarroya S, Llobera M, Baucells J, Lejeune M. CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients. Breast Cancer. 2022 Jul;29(4):618-635. doi: 10.1007/s12282-022-01336-2.
- Li Z, Ju X, Silveira PA, Abadir E, Hsu WH, Hart DNJ, Clark GJ. CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential. Front Immunol. 2019 Jun 7;10:1312. doi: 10.3389/fimmu.2019.01312.
- 5. Gao X, Dong QZ. Advance in metabolism and target therapy in breast cancer stem cells. World J Stem Cells. 2020 Nov 26;12(11):1295-1306. doi: 10.4252/wjsc.v12.i11.1295.
- Vadhan A, Hou MF, Vijayaraghavan P, Wu YC, Hu SC, Wang YM, Cheng TL, Wang YY, Yuan SF. CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2. Biomedicines. 2022 Oct 5;10(10):2488. doi: 10.3390/biomedicines10102488.
- Kuang Y, Wang S, Tang L, Hai J, Yan G, Liao L. Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H+-ATPase expression and activity. Oncol Lett. 2018 May;15(5):7279-7290. doi: 10.3892/ol.2018.8199.
- Cheriyath V, Kaur J, Davenport A, Khalel A, Chowdhury N, Gaddipati L. G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS. Br J Cancer. 2018 Jul;119(1):52-64. doi: 10.1038/s41416-018-0137-3.
- Stein MF, Lang S, Winkler TH, Deinzer A, Erber S, Nettelbeck DM, Naschberger E, Jochmann R, Stürzl M, Slany RK, Werner T, Steinkasserer A, Knippertz I. Multiple interferon regulatory factor and NF-κB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells. Mol Cell Biol. 2013 Apr;33(7):1331-44. doi: 10.1128/MCB.01051-12.
- Grosche L, Knippertz I, König C, Royzman D, Wild AB, Zinser E, Sticht H, Muller YA, Steinkasserer A, Lechmann M. The CD83 Molecule – An Important Immune Checkpoint. Front Immunol. 2020 Apr 17;11:721. doi: 10.3389/fimmu.2020.00721.